JAAD International最新文献_第3页

Impact of disease cyclicity on quality-of-life impairment—A mixed method explanatory study

JAAD International Pub Date : 2025-02-01 DOI: 10.1016/j.jdin.2024.09.007

Ying Shan Cheung MD , Winston Tham Zhi Wen , Ashvin R. Chundayil , Phillip Phan PhD , Ellie Choi Ci-En MBBS, MRCP

{"title":"Impact of disease cyclicity on quality-of-life impairment—A mixed method explanatory study","authors":"Ying Shan Cheung MD , Winston Tham Zhi Wen , Ashvin R. Chundayil , Phillip Phan PhD , Ellie Choi Ci-En MBBS, MRCP","doi":"10.1016/j.jdin.2024.09.007","DOIUrl":"10.1016/j.jdin.2024.09.007","url":null,"abstract":"<div><h3>Background</h3><div>Disease cyclicity, a composite measure of unpredictable and daily fluctuations of symptoms, strongly predicts quality-of-life (QoL) impairment.</div></div><div><h3>Objective</h3><div>To explore the mechanisms by which cyclicity impacts QoL.</div></div><div><h3>Methods</h3><div>1:1 semi-structured interviews were conducted and qualitatively analyzed using grounded theory. Common themes were identified and used to derive a theoretical framework.</div></div><div><h3>Results</h3><div>Twenty-three adults, (median age 28.5, range 20-72) with a range of chronic inflammatory diseases including eczema, psoriasis, and inflammatory arthritis were prospectively recruited. Cyclicity, characterized by unpredictability, uncontrollability, and lability, contributed to a varying productivity and inconsistent ability in performing daily activities. Challenges intensified if external expectations of the patient were inconsistent with their fluctuating ability. Coping abilities, shaped by internal and external factors, moderated the relationship between cyclicity and QoL impairment.</div></div><div><h3>Limitations</h3><div>Qualitative interviews assume patients have accurate insights into their own behaviors. The generalizability of findings may be limited in other populations.</div></div><div><h3>Conclusion</h3><div>Disease cyclicity defines many inflammatory diseases. This study provides a theoretical framework for understanding and managing the challenges patients with a cyclical condition face.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 180-187"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis 随机安慰剂对照试验中口服Janus激酶抑制剂治疗期间感染的风险：系统回顾和荟萃分析。

JAAD International Pub Date : 2025-02-01 DOI: 10.1016/j.jdin.2024.09.012

Daniel Isufi BSc(Med) , Mikkel Bak Jensen MD , Nikolai Loft MD, PhD , Lone Skov MD, PhD, DMSc , Jesper Elberling MD, PhD , Farzad Alinaghi MD, PhD

{"title":"Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis","authors":"Daniel Isufi BSc(Med) , Mikkel Bak Jensen MD , Nikolai Loft MD, PhD , Lone Skov MD, PhD, DMSc , Jesper Elberling MD, PhD , Farzad Alinaghi MD, PhD","doi":"10.1016/j.jdin.2024.09.012","DOIUrl":"10.1016/j.jdin.2024.09.012","url":null,"abstract":"<div><div>Janus kinase (JAK) inhibitors block pathways involved in inflammation and immune response, making JAK inhibitors useful in the treatment of various diseases. While the efficacy of these drugs has been proven in several studies, their safety profile needs to be further investigated. In this systematic review and meta-analysis, we examined the risk of infections during treatment with oral JAK inhibitors with no concomitant treatment compared to placebo in phase 2 and 3 randomized, placebo-controlled trials. The medical databases PubMed, Web of Science, and EMBASE were searched from inception through February 2024, yielding 13,567 nonduplicate articles, of which 69 were included in the final quantitative analysis. Overall, we found that treatment with oral JAK inhibitors was associated with an increased risk of infections compared to placebo across all indications (relative risk: 1.39 [95% CI: 1.096-1.76, <em>P</em> = .0067]) and in dermatologic indications (relative risk: 1.46 [95% CI, 1.10-1.93, <em>P</em> = .0097]). Remarkably, an increased risk of herpes zoster infections was found in dermatologic indications but not in nondermatologic indications. In conclusion, we identified a significantly increased risk of developing infections during treatment with oral JAK inhibitors compared to placebo across indications. In sub-analyses, we additionally found an increased risk of herpes zoster in dermatologic indications.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 106-116"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the appropriateness of skin cancer prevention recommendations obtained from an online chat-based artificial intelligence model 评估从基于在线聊天的人工智能模型获得的皮肤癌预防建议的适当性。

JAAD International Pub Date : 2025-02-01 DOI: 10.1016/j.jdin.2024.07.028

Elise M. Cai BS, Pirunthan Pathmarajah MD, Roxana Daneshjou MD, PhD, Justin M. Ko MD, MBA, Albert S. Chiou MD, MBA

引用次数: 0

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors 在接受免疫检查点抑制剂治疗的转移性黑色素瘤患者中，NRAS肿瘤突变与皮肤不良事件发生率降低相关。

JAAD International Pub Date : 2025-02-01 DOI: 10.1016/j.jdin.2024.11.004

Michael S. Chang MD , Jordan T. Said MD , Elliot H. Akama-Garren PhD , Nicole Trepanowski MD , Ai-Tram N. Bui MD , Anita Giobbie-Hurder MS , Nicole R. LeBoeuf MD, MPH , Rebecca I. Hartman MD, MPH

引用次数: 0

Treatment of Merkel cell carcinoma in organ transplant recipients—A systematic review

JAAD International Pub Date : 2025-01-31 DOI: 10.1016/j.jdin.2025.01.007

Darryl Chin Kai Xian , Choon Chiat Oh MBBS, MSc

{"title":"Treatment of Merkel cell carcinoma in organ transplant recipients—A systematic review","authors":"Darryl Chin Kai Xian , Choon Chiat Oh MBBS, MSc","doi":"10.1016/j.jdin.2025.01.007","DOIUrl":"10.1016/j.jdin.2025.01.007","url":null,"abstract":"<div><h3>Background</h3><div>There are no clear treatment guidelines for solid organ transplantation (SOT) patients with Merkel cell carcinoma (MCC) despite increased incidence rates.</div></div><div><h3>Objective</h3><div>To review treatment outcomes of MCC patients with prior SOT.</div></div><div><h3>Methods</h3><div>A systematic review (Prospective Register of Systematic Reviews CRD42024569200) of studies that reported treatment modalities and outcomes for MCC patients with SOT were selected. Databases screened included PubMed, Web of Science, Scopus, and Embase.</div></div><div><h3>Results</h3><div>Thirty articles comprising 21 case reports, 8 cohort studies, and 1 clinical trial were included. Treatment modalities reported in case reports and clinical trials included surgery (77.7%), radiotherapy (62.9%), and chemotherapy (25.9%), with 3 patients receiving immune checkpoint inhibitors and 1 patient receiving an oncolytic virus. Cohort studies reported varying usage of surgery, radiotherapy, chemotherapy, and immunosuppression regime modifications.</div></div><div><h3>Limitations</h3><div>Heterogeneity in methodologies and data reporting of studies included impeded meaningful comparisons. Lack of stratification of immunosuppressed populations in the excluded studies reduced the available patient data for comparison.</div></div><div><h3>Conclusion</h3><div>Oncolytic virotherapy has the potential to mediate a localized, targeted response with minimal side effects in SOT patients. Inclusion of SOT patients with MCC into future clinical trials involving immunotherapy and immunosuppression combination therapies is needed to establish future treatment guidelines.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 75-82"},"PeriodicalIF":0.0,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors associated with cytomegalovirus infection in patients with drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms (DIHS/DRESS)

JAAD International Pub Date : 2025-01-31 DOI: 10.1016/j.jdin.2025.01.009

Fumi Miyagawa MD, PhD , Yoshiko Mizukawa MD, PhD , Yasuaki Hayashino MD, PhD , Yuki Nakamura-Nishimura MD, PhD , Hideo Asada MD, PhD

引用次数: 0

Relative risk of keloids in patients with chronic inflammatory skin disorders

JAAD International Pub Date : 2025-01-28 DOI: 10.1016/j.jdin.2025.01.006

Raphaella Lambert BA, Hannah Verma BA, Grace Rabinowitz BA, Nicholas Gulati MD, PhD, Jonas A. Adalsteinsson MD, PhD

引用次数: 0

Ethics of artificial intelligence-assisted image interpretation in dermatopathology

JAAD International Pub Date : 2025-01-27 DOI: 10.1016/j.jdin.2025.01.005

Hayden Smith BA , Travis Blalock MD , Benjamin K. Stoff MD, MA